1-15 of 15
Tim M. Illidge
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hajek, MD PhD, Wojciech Jurczak, MD PhD, Ella Willenbacher, MD, Unn Merete Fagerli, MD PhD, Aleš Obr, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Åse Østengen, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2879.
https://doi.org/10.1182/blood-2018-99-110555
Published: 2018
Journal Articles

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Steven M. Horwitz, MD, Owen A. O'Connor, MD, PhD, Barbara Pro, MD, Tim M. Illidge, MDPhD, Michelle A. Fanale, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, MD PhD, Tatyana A. Feldman, MD, Anne Lennard, MBBS,FRCP, FRCPath, David Belada, MD PhD, Árpád Illés, Kensei Tobinai, MD PhD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R. Shustov, MD, Andreas Hüttmann, MD, Kerry J Savage, BSc, MD MSc, Sam Yuen, Pier Luigi Zinzani, MD, Zhaowei Hua, Meredith Little, MPH, Shangbang Rao, PhD, Joseph Woolery, PharmD, Thomas Manley, MD, Lorenz Trümper, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 997.
https://doi.org/10.1182/blood-2018-99-110563
Published: 2018
Journal Articles

Patient and Physician Preferences for Front-Line Treatment of Advanced Stage Hodgkin Lymphoma in Germany, France and the United Kingdom

Paul Broeckelmann, Aspasia Stamatoullas, MD, Suzanne McMullen, Ben Wilson, MSc, Kerstin Mueller, MSc, MA, PhD, Sarah Goring, MSc, Erin Zagadailov, PharmD, MS, Ashish Gautam, PhD, Dirk Huebner, MD, Mehul Dalal, PhD, Tim M. Illidge, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4082.
https://doi.org/10.1182/blood.V130.Suppl_1.4082.4082
Published: 2017
Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hájek, MD, Wojciech Jurczak, PhDMD, Ella Willenbacher, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Laurie Baylor Curtis, MSc, Marianne Bloma, MSc, Simon Turner, PhD, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Unn Merete Fagerli, MD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte
Journal: Blood
Blood (2017) 130 (Supplement 1): 2769.
https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769
Published: 2017
Journal Articles

Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Michelle A. Fanale, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert W. Chen, MD, Andrew Davies, PhD, Tim M. Illidge, MDPhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R. Shustov, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2790.
https://doi.org/10.1182/blood.V130.Suppl_1.2790.2790
Published: 2017
Journal Articles

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

Jamie Honeychurch, Waleed Alduaij, Mahsa Azizyan, Eleanor J. Cheadle, Helene Pelicano, Andrei Ivanov, Peng Huang, Mark S. Cragg, Tim M. Illidge
Journal: Blood
Blood (2012) 119 (15): 3523–3533.
https://doi.org/10.1182/blood-2011-12-395541
Published: 2012
Includes: Multimedia, Supplemental data
Journal Articles

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, Eleanor J. Cheadle, Sandeep Potluri, Sean H. Lim, Kazuyuki Shimada, Claude H. T. Chan, Alison Tutt, Stephen A. Beers, Martin J. Glennie, Mark S. Cragg, Tim M. Illidge
Journal: Blood
Blood (2011) 117 (17): 4519–4529.
https://doi.org/10.1182/blood-2010-07-296913
Published: 2011
Includes: Multimedia, Supplemental data
Journal Articles

The future of anti-CD20 monoclonal antibodies: are we making progress?

Waleed Alduaij, Tim M. Illidge
Journal: Blood
Blood (2011) 117 (11): 2993–3001.
https://doi.org/10.1182/blood-2010-07-298356
Published: 2011
Journal Articles

Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates

Mark S. Cragg, Waleed Alduaij, Christian Klein, Pablo Umana, Martin J. Glennie, Tim M. Illidge
Journal: Blood
Blood (2010) 116 (17): 3373–3374.
https://doi.org/10.1182/blood-2010-07-291054
Published: 2010
Journal Articles

Phase 1/2 study of fractionated 131 I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

Clinical Trials & Observations
Tim M. Illidge, Mike Bayne, Nicholas S. Brown, Samantha Chilton, Mark S. Cragg, Martin J. Glennie, Yong Du, Valerie Lewington, James Smart, James Thom, Maureen Zivanovic, Peter W. M. Johnson
Journal: Blood
Blood (2009) 113 (7): 1412–1421.
https://doi.org/10.1182/blood-2008-08-175653
Published: 2009
Journal Articles

Macrophage Depletion Can Enhance Combined Radiation and Anti-CD40 Monoclonal Antibody Therapy of B-Cell Lymphoma.

Jamie Honeychurch, PhD, Tim M. Illidge, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2501.
https://doi.org/10.1182/blood.V108.11.2501.2501
Published: 2006
Journal Articles

Treatment with the Anti-CD20 Antibody (B1) and Irradiation Result in Synergistic Cytotoxicity That Is Dependent on MAPK Activation.

Andrei Ivanov, MD, Mark S. Cragg, PhD, Tim M. Illidge, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2508.
https://doi.org/10.1182/blood.V108.11.2508.2508
Published: 2006
Journal Articles

Phase I/II Study of Fractionated Radioimmunotherapy (RIT) in Relapsed Low Grade Non-Hodgkin’s Lymphoma (NHL).

Tim M. Illidge, MD, PhD, Mike C. Bayne, MD, Maureen Zivanovic, Yong Du, MD, Valerie Lewington, MD, Johnson W. Peter, MD
Journal: Blood
Blood (2004) 104 (11): 131.
https://doi.org/10.1182/blood.V104.11.131.131
Published: 2004
Journal Articles

Cyclophosphamide Induced CD11b + Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma.

Jamie Honeychurch, PhD, Martin J. Glennie, PhD, Peter W. Johnson, MD, Tim M. Illidge, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 3280.
https://doi.org/10.1182/blood.V104.11.3280.3280
Published: 2004
Journal Articles

Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy

Yong Du, Jamie Honeychurch, Mark S. Cragg, Mike Bayne, Martin J. Glennie, Peter W. M. Johnson, Tim M. Illidge
Journal: Blood
Blood (2004) 103 (4): 1485–1494.
https://doi.org/10.1182/blood-2003-06-2037
Published: 2004